Loading…
A presentation, treatment, and survival analysis of primary cardiac lymphoma cases reported from 2009 to 2019
The heart is a rare primary site of lymphoma, and cardiac involvement is thought to bring a poorer prognosis. A framework of known clinical presentations, diagnostic features, disease complications, treatments, and outcomes to improve prognostication was constructed by a systematic review in 2011. H...
Saved in:
Published in: | International journal of hematology 2020-07, Vol.112 (1), p.65-73 |
---|---|
Main Authors: | , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c399t-542495a080fb4516633635c8aa4b9c1956ad5f718814a91df014c9a701e643cb3 |
---|---|
cites | cdi_FETCH-LOGICAL-c399t-542495a080fb4516633635c8aa4b9c1956ad5f718814a91df014c9a701e643cb3 |
container_end_page | 73 |
container_issue | 1 |
container_start_page | 65 |
container_title | International journal of hematology |
container_volume | 112 |
creator | Chen, Haoguang Qian, Shenxian Shi, Pengfei Liu, Lirong Yang, Fan |
description | The heart is a rare primary site of lymphoma, and cardiac involvement is thought to bring a poorer prognosis. A framework of known clinical presentations, diagnostic features, disease complications, treatments, and outcomes to improve prognostication was constructed by a systematic review in 2011. However, some aspects must be discussed further in light of recent advances in lymphoma research. We collected cardiac lymphoma case reports published from January 2009 to January 2019, collected statistics from each patient, and performed a systematic analysis. The epidemiological characteristics, clinical manifestations, treatments, responses, and survival of primary cardiac lymphoma (PCL) patients are described. We obtained 158 cases of heart lymphoma, of which 101 were defined as PCL. There were more male than female cases. Most cases were diffuse large B-cell lymphoma. Six cases of PCL in cardiac myxomas were described. Patients with arrhythmia had shorter progression-free survival compared those without (HR 0.334, 95% CI 0.112–0.999, log-rank
P
= 0.042). Surgery did not improve patients’ long-term prognosis or reduce the risk of death within 1 month. These data suggest that central nervous system prophylaxis is necessary. The overall survival was longer than that in data from 1949 to 2009. |
doi_str_mv | 10.1007/s12185-020-02881-2 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2389693543</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2389693543</sourcerecordid><originalsourceid>FETCH-LOGICAL-c399t-542495a080fb4516633635c8aa4b9c1956ad5f718814a91df014c9a701e643cb3</originalsourceid><addsrcrecordid>eNp9kc9O3DAQxi1EBcvCC3BAlrj0QNoZ_0nsI1q1tBJSL-05mnUcCErirZ0g7dvwLH0yTHehUg8crJHt33yfZj7GzhE-IUD1OaFAowsQkI8xWIgDtkBT6kJWlTpkC7BCF7pCOGYnKT0AYAWqOmLHUgijZQkLNl7zTfTJjxNNXRiv-BQ9TUO-X3EaG57m-Ng9Uv_niUbqt6lLPLS5pRsobrmj2HTkeL8dNvdhoPyQfOLRb0KcfMPbGAYuACyfQq5oT9mHlvrkz_Z1yX59_fJz9a24_XHzfXV9Wzhp7VRoJZTVBAbatdJYllKWUjtDpNbWodUlNbqtMA-tyGLTAipnqQL0pZJuLZfs4053E8Pv2aepHrrkfN_T6MOcaiGNLa3USmb08j_0IcwxD5sphdKAfDFfMrGjXAwpRd_W-x3UCPVLGvUujTqnUf9NI3ss2cVeel4PvnlreV1_BuQOSPlrvPPxn_c7ss96ZJO2</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2413803336</pqid></control><display><type>article</type><title>A presentation, treatment, and survival analysis of primary cardiac lymphoma cases reported from 2009 to 2019</title><source>Springer Nature</source><creator>Chen, Haoguang ; Qian, Shenxian ; Shi, Pengfei ; Liu, Lirong ; Yang, Fan</creator><creatorcontrib>Chen, Haoguang ; Qian, Shenxian ; Shi, Pengfei ; Liu, Lirong ; Yang, Fan</creatorcontrib><description>The heart is a rare primary site of lymphoma, and cardiac involvement is thought to bring a poorer prognosis. A framework of known clinical presentations, diagnostic features, disease complications, treatments, and outcomes to improve prognostication was constructed by a systematic review in 2011. However, some aspects must be discussed further in light of recent advances in lymphoma research. We collected cardiac lymphoma case reports published from January 2009 to January 2019, collected statistics from each patient, and performed a systematic analysis. The epidemiological characteristics, clinical manifestations, treatments, responses, and survival of primary cardiac lymphoma (PCL) patients are described. We obtained 158 cases of heart lymphoma, of which 101 were defined as PCL. There were more male than female cases. Most cases were diffuse large B-cell lymphoma. Six cases of PCL in cardiac myxomas were described. Patients with arrhythmia had shorter progression-free survival compared those without (HR 0.334, 95% CI 0.112–0.999, log-rank
P
= 0.042). Surgery did not improve patients’ long-term prognosis or reduce the risk of death within 1 month. These data suggest that central nervous system prophylaxis is necessary. The overall survival was longer than that in data from 1949 to 2009.</description><identifier>ISSN: 0925-5710</identifier><identifier>EISSN: 1865-3774</identifier><identifier>DOI: 10.1007/s12185-020-02881-2</identifier><identifier>PMID: 32285360</identifier><language>eng</language><publisher>Singapore: Springer Singapore</publisher><subject>Arrhythmia ; B-cell lymphoma ; Case reports ; Central nervous system ; Complications ; Diagnostic systems ; Epidemiology ; Heart ; Hematology ; Lymphocytes B ; Lymphoma ; Medical prognosis ; Medical treatment ; Medicine ; Medicine & Public Health ; Oncology ; Original Article ; Patients ; Prognosis ; Prophylaxis ; Statistical analysis ; Surgery ; Survival ; Survival analysis</subject><ispartof>International journal of hematology, 2020-07, Vol.112 (1), p.65-73</ispartof><rights>Japanese Society of Hematology 2020</rights><rights>Japanese Society of Hematology 2020.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c399t-542495a080fb4516633635c8aa4b9c1956ad5f718814a91df014c9a701e643cb3</citedby><cites>FETCH-LOGICAL-c399t-542495a080fb4516633635c8aa4b9c1956ad5f718814a91df014c9a701e643cb3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32285360$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chen, Haoguang</creatorcontrib><creatorcontrib>Qian, Shenxian</creatorcontrib><creatorcontrib>Shi, Pengfei</creatorcontrib><creatorcontrib>Liu, Lirong</creatorcontrib><creatorcontrib>Yang, Fan</creatorcontrib><title>A presentation, treatment, and survival analysis of primary cardiac lymphoma cases reported from 2009 to 2019</title><title>International journal of hematology</title><addtitle>Int J Hematol</addtitle><addtitle>Int J Hematol</addtitle><description>The heart is a rare primary site of lymphoma, and cardiac involvement is thought to bring a poorer prognosis. A framework of known clinical presentations, diagnostic features, disease complications, treatments, and outcomes to improve prognostication was constructed by a systematic review in 2011. However, some aspects must be discussed further in light of recent advances in lymphoma research. We collected cardiac lymphoma case reports published from January 2009 to January 2019, collected statistics from each patient, and performed a systematic analysis. The epidemiological characteristics, clinical manifestations, treatments, responses, and survival of primary cardiac lymphoma (PCL) patients are described. We obtained 158 cases of heart lymphoma, of which 101 were defined as PCL. There were more male than female cases. Most cases were diffuse large B-cell lymphoma. Six cases of PCL in cardiac myxomas were described. Patients with arrhythmia had shorter progression-free survival compared those without (HR 0.334, 95% CI 0.112–0.999, log-rank
P
= 0.042). Surgery did not improve patients’ long-term prognosis or reduce the risk of death within 1 month. These data suggest that central nervous system prophylaxis is necessary. The overall survival was longer than that in data from 1949 to 2009.</description><subject>Arrhythmia</subject><subject>B-cell lymphoma</subject><subject>Case reports</subject><subject>Central nervous system</subject><subject>Complications</subject><subject>Diagnostic systems</subject><subject>Epidemiology</subject><subject>Heart</subject><subject>Hematology</subject><subject>Lymphocytes B</subject><subject>Lymphoma</subject><subject>Medical prognosis</subject><subject>Medical treatment</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Oncology</subject><subject>Original Article</subject><subject>Patients</subject><subject>Prognosis</subject><subject>Prophylaxis</subject><subject>Statistical analysis</subject><subject>Surgery</subject><subject>Survival</subject><subject>Survival analysis</subject><issn>0925-5710</issn><issn>1865-3774</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp9kc9O3DAQxi1EBcvCC3BAlrj0QNoZ_0nsI1q1tBJSL-05mnUcCErirZ0g7dvwLH0yTHehUg8crJHt33yfZj7GzhE-IUD1OaFAowsQkI8xWIgDtkBT6kJWlTpkC7BCF7pCOGYnKT0AYAWqOmLHUgijZQkLNl7zTfTJjxNNXRiv-BQ9TUO-X3EaG57m-Ng9Uv_niUbqt6lLPLS5pRsobrmj2HTkeL8dNvdhoPyQfOLRb0KcfMPbGAYuACyfQq5oT9mHlvrkz_Z1yX59_fJz9a24_XHzfXV9Wzhp7VRoJZTVBAbatdJYllKWUjtDpNbWodUlNbqtMA-tyGLTAipnqQL0pZJuLZfs4053E8Pv2aepHrrkfN_T6MOcaiGNLa3USmb08j_0IcwxD5sphdKAfDFfMrGjXAwpRd_W-x3UCPVLGvUujTqnUf9NI3ss2cVeel4PvnlreV1_BuQOSPlrvPPxn_c7ss96ZJO2</recordid><startdate>20200701</startdate><enddate>20200701</enddate><creator>Chen, Haoguang</creator><creator>Qian, Shenxian</creator><creator>Shi, Pengfei</creator><creator>Liu, Lirong</creator><creator>Yang, Fan</creator><general>Springer Singapore</general><general>Springer Nature B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7T5</scope><scope>7T7</scope><scope>7TM</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20200701</creationdate><title>A presentation, treatment, and survival analysis of primary cardiac lymphoma cases reported from 2009 to 2019</title><author>Chen, Haoguang ; Qian, Shenxian ; Shi, Pengfei ; Liu, Lirong ; Yang, Fan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c399t-542495a080fb4516633635c8aa4b9c1956ad5f718814a91df014c9a701e643cb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Arrhythmia</topic><topic>B-cell lymphoma</topic><topic>Case reports</topic><topic>Central nervous system</topic><topic>Complications</topic><topic>Diagnostic systems</topic><topic>Epidemiology</topic><topic>Heart</topic><topic>Hematology</topic><topic>Lymphocytes B</topic><topic>Lymphoma</topic><topic>Medical prognosis</topic><topic>Medical treatment</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Oncology</topic><topic>Original Article</topic><topic>Patients</topic><topic>Prognosis</topic><topic>Prophylaxis</topic><topic>Statistical analysis</topic><topic>Surgery</topic><topic>Survival</topic><topic>Survival analysis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chen, Haoguang</creatorcontrib><creatorcontrib>Qian, Shenxian</creatorcontrib><creatorcontrib>Shi, Pengfei</creatorcontrib><creatorcontrib>Liu, Lirong</creatorcontrib><creatorcontrib>Yang, Fan</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Immunology Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Nucleic Acids Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chen, Haoguang</au><au>Qian, Shenxian</au><au>Shi, Pengfei</au><au>Liu, Lirong</au><au>Yang, Fan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A presentation, treatment, and survival analysis of primary cardiac lymphoma cases reported from 2009 to 2019</atitle><jtitle>International journal of hematology</jtitle><stitle>Int J Hematol</stitle><addtitle>Int J Hematol</addtitle><date>2020-07-01</date><risdate>2020</risdate><volume>112</volume><issue>1</issue><spage>65</spage><epage>73</epage><pages>65-73</pages><issn>0925-5710</issn><eissn>1865-3774</eissn><abstract>The heart is a rare primary site of lymphoma, and cardiac involvement is thought to bring a poorer prognosis. A framework of known clinical presentations, diagnostic features, disease complications, treatments, and outcomes to improve prognostication was constructed by a systematic review in 2011. However, some aspects must be discussed further in light of recent advances in lymphoma research. We collected cardiac lymphoma case reports published from January 2009 to January 2019, collected statistics from each patient, and performed a systematic analysis. The epidemiological characteristics, clinical manifestations, treatments, responses, and survival of primary cardiac lymphoma (PCL) patients are described. We obtained 158 cases of heart lymphoma, of which 101 were defined as PCL. There were more male than female cases. Most cases were diffuse large B-cell lymphoma. Six cases of PCL in cardiac myxomas were described. Patients with arrhythmia had shorter progression-free survival compared those without (HR 0.334, 95% CI 0.112–0.999, log-rank
P
= 0.042). Surgery did not improve patients’ long-term prognosis or reduce the risk of death within 1 month. These data suggest that central nervous system prophylaxis is necessary. The overall survival was longer than that in data from 1949 to 2009.</abstract><cop>Singapore</cop><pub>Springer Singapore</pub><pmid>32285360</pmid><doi>10.1007/s12185-020-02881-2</doi><tpages>9</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0925-5710 |
ispartof | International journal of hematology, 2020-07, Vol.112 (1), p.65-73 |
issn | 0925-5710 1865-3774 |
language | eng |
recordid | cdi_proquest_miscellaneous_2389693543 |
source | Springer Nature |
subjects | Arrhythmia B-cell lymphoma Case reports Central nervous system Complications Diagnostic systems Epidemiology Heart Hematology Lymphocytes B Lymphoma Medical prognosis Medical treatment Medicine Medicine & Public Health Oncology Original Article Patients Prognosis Prophylaxis Statistical analysis Surgery Survival Survival analysis |
title | A presentation, treatment, and survival analysis of primary cardiac lymphoma cases reported from 2009 to 2019 |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T07%3A37%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20presentation,%20treatment,%20and%20survival%C2%A0analysis%20of%20primary%20cardiac%20lymphoma%20cases%20reported%20from%202009%20to%202019&rft.jtitle=International%20journal%20of%20hematology&rft.au=Chen,%20Haoguang&rft.date=2020-07-01&rft.volume=112&rft.issue=1&rft.spage=65&rft.epage=73&rft.pages=65-73&rft.issn=0925-5710&rft.eissn=1865-3774&rft_id=info:doi/10.1007/s12185-020-02881-2&rft_dat=%3Cproquest_cross%3E2389693543%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c399t-542495a080fb4516633635c8aa4b9c1956ad5f718814a91df014c9a701e643cb3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2413803336&rft_id=info:pmid/32285360&rfr_iscdi=true |